Here are the 10-K annual reports from Nu-Med Plus Inc (NUMD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow NUMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUMD filings page.
Nu-Med Plus, Inc. is a development-stage medical device company focused on nitric oxide delivery systems for hospital, clinical, portable, disposable and research applications. Product development has been suspended until new capital is raised, and the company has not yet submitted any devices for FDA approval.
At December 31, 2025, Nu-Med had total assets of $7,911, including cash of $661, and total liabilities of $279,189, reflecting a highly strained balance sheet. The company generated no revenue in 2025, incurred operating expenses of $48,955 and interest expense of $7,227, resulting in a net loss of $56,182, narrower than the prior year’s $68,345 loss.
Management and the auditor both highlight substantial doubt about Nu-Med’s ability to continue as a going concern. The company estimates it needs $1,250,000 over the next year to execute its plan of operations but currently has no committed financing and expects to rely on loans and equity sales. Internal control over financial reporting is assessed as ineffective due to limited staffing and lack of segregation of duties.
Nu-Med qualifies as an emerging growth company and smaller reporting company and intends to use reduced disclosure and extended accounting standard transition provisions. It holds two approved patents and one pending for its nitric oxide systems, but with only two employees and intense competition from much larger device and pharmaceutical companies, commercialization of any product is described as being years away.